Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02580045 : Pharmacokinetics of Systemic Anti-Cancer Therapies in the Cerebrospinal Fluid (CSF) of Patients With Advanced Cancer
PhaseN/A
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

1. Metastatic cancer patients on systemic anti-cancer therapy (chemotherapy, endocrine
therapy, HER2 targeted therapy, immune therapy).

2. Patients must be able to have a lumbar puncture within 2 half-lives of the last dose
of systemic therapy.

3. Patients undergoing an LP for any reason with known advanced cancer on systemic
anti-cancer therapy are eligible.

4. Patients with new or previously treated brain metastases are eligible.

5. Patients may have received prior stereotactic radiosurgery to the brain and/or whole
brain radiation.

6. No limitations on prior systemic or intrathecal therapies.

7. There are no restrictions on systemic therapy at enrollment.

8. Laboratory criteria: normal renal function: creatinine < 1.5 x upper limit of normal
(ULN)), liver function: bilirubin < 1.5 x ULN, transaminases < 2 x ULN, except in
known hepatic disease, wherein may be < 5 x ULN, and blood counts: WBC ? 2.0,
Neutrophils ?1500, platelets ?100,000, Hemoglobin ? 10.

9. Age > 18 years

10. Patients must have the ability to give informed consent.

11. Patients must have a signed informed consent form prior to enrollment on study.

Exclusion Criteria:

1. No history of lumbar surgery or other pre-existing spinal conditions that would
preclude a safe, reliable lumbar puncture.

2. Patients should have no significant psychiatric illness or medical illness that would
preclude the ability to comply with the protocol.
LinksPermanent Link to THIS page: http://virtualtrials.com/nct/display1trial.cfm?nct=NCT02580045      |      Link to official Clinicaltrials.gov listing
Locations
Durham, North Carolina
Facility: Duke University Medical Center
Investigator: Kimberly Blackwell, MD
Contact: Kim Riley Phone: 919-660-1278
Click HERE to send email to this center




Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites